Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
GOSS Stock Chart & Stats
$2.26
-$0.10(-9.01%)
At close: 4:00 PM EST
$2.26
-$0.10(-9.01%)
Day’s Range― - ―
52-Week Range$0.76 - $3.87
Previous CloseN/A
Volume602.63K
Average Volume (3M)4.73M
Market Cap
$539.29M
Enterprise Value$719.00M
Total Cash (Recent Filing)$180.22M
Total Debt (Recent Filing)$202.88M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding231,456,250
10 Day Avg. Volume5,742,655
30 Day Avg. Volume4,728,451
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.94
Price to Sales (P/S)1.78
P/FCF Ratio-59.01
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue16.32
Enterprise Value/Gross Profit16.32
Enterprise Value/Ebitda-4.93
Forecast
1Y Price Target
$11.33Price Target Upside401.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityPositive TORREY results in sicker patients combined with continued improvement in the open‑label extension reinforce expectations for meaningful and durable clinical benefit.
Clinical Trial DesignPROSERA's larger enrollment and use of multiple endpoints increases the likelihood that pivotal data will be interpretable and that true drug effects can be detected.
Mechanism Of ActionSeralutinib's targeted inhibition of pathways linked to vascular remodeling, inflammation, and fibrosis supports its positioning as a potential disease‑modifying therapy rather than a short‑term symptomatic treatment.
Bears Say
Extension Attrition And BiasHigh attrition in the open‑label extension raises concern that long‑term improvements may reflect survivorship bias and not represent outcomes for the full treated population.
Placebo Variability RiskUnexpectedly strong or noisy placebo responses could mask the treatment effect and reduce the observed benefit even if the drug is active.
Subgroup‑dependent EfficacyClinical benefits concentrated in specific, sicker patient subgroups while the overall study population showed muted results may limit confidence in broad clinical applicability and commercial uptake.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.76 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Gossamer Bio Inc’s market cap is $539.29M.
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is Mar 13, 2026 which is in 29 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on Nov 05, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is -0.19.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 231,456,250 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (401.33% Upside)
$11.33 (401.33% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.49%
Trailing 12-Months
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Stock 12 Month Forecast
Average Price Target
$11.33
▲(401.33% Upside)
Technical Analysis
Ownership Overview
10.24% Insiders
9.47% Mutual Funds
<0.01% Other Institutional Investors
66.08% Public Companies and Individual Investors